AstraZeneca wins European approval for opioid-induced constipation drug; EU health officials investigate GVK Bio for alleged fraud;

@FiercePharma: Did Merck pay $3B too much for Cubist? Analysts weigh impact of Cubicin patent loss. Story | Follow @FiercePharma

@CarlyHFierce: AbbVie's Humira competition begins with Cadila's biosimilar launch in India. More | Follow @CarlyHFierce

> AstraZeneca ($AZN) scored European Union approval for Movantik, its opioid-induced constipation drug developed with Nektar Therapeutics. Story

> European Union health officials are cracking down on contract research firm GVK Bio after several allegations of fraud at its clinical facility in India. More

> Dutch pharmaceutical outfit Brocacef is snatching up medical supplies and equipment provider Mediq to create a company with combined sales of €2.1 billion ($2.6 billion). Story

> Takeda revealed promising Phase III study data showing that Hodgkin's lymphoma (HL) patients who received its Adcetris therapy after a stem cell transplant had a significantly improved survival rate compared to patients who received a placebo. More

> AstraZeneca snatched up the lease on a new, 29,000-square-foot property in Cambridge, U.K. The building will accommodate between 150 and 200 members of the company's corporate staff. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: Edwards gains option to acquire startup CardioKinetix in $50M financing. Article | Follow @FierceMedDev

@EmilyWFierce: Stryker's OtisMed to pay more than $80M to settle DOJ case over knee replacement surgical devices. Story | Follow @EmilyWFierce

> Eurofins Scientific snaps up Boston Heart Diagnostics for $140M. Story

> Brain sensors go wireless in Brown University study. More

> Edwards looks to TAVR to convince Wall Street it can go higher after doubling in 2014. Article

Biotech News

@FierceBiotech: Bluebird posts more promising results with its rare disease therapy. Story | Follow @FierceBiotech

@DamianFierce: So the billionaire Russian oligarch who bought Watson's Nobel medal for $4.1 million is giving it back because hey. More | Follow @DamianFierce

> Pfizer strikes another immunotherapy deal to widen its oncology pipeline. News

> Lilly and Incyte's oral arthritis drug aces its first Phase III test. Story

> Circassia looks to higher doses to salvage ragweed drug after PhIIb miss. Article

Biotech Research News

> Epizyme showcases a successful preclinical lymphoma program for third target. More

> MicroRNA holds clues to predicting progression-free myeloma survival. Report

> New malaria drug unleashes an immune system assault on infected cells. Story

> Could alpha secretase offer a better approach to fighting Alzheimer's? More

> PKC-epsilon pathway offers a new line of attack against cancer cells. Article

Pharma Manufacturing News

> India's Zydus Cadila finds blood pressure med has embedded brown spots. Story

> Ferring preps for first U.S. plant opening as it moves to New Jersey campus. More

> FDA notches a win after Tennessee compounder pleads guilty. Report

> Meda drops Recipharm contract; plant may be forced to close. Story

> Daewoong inks deal to build $188M facility in South Korea. Article

And Finally… Harvard University researchers are moving one step closer to creating a fat-burning pill that could one day replace the treadmill. Story

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.